구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201)) Beam Therapeutics Inc.·T-Cell Acute Lymphoblastic Leukemi… 16 trials |
|---|---|
Overview Program | Allogeneic anti-CD7 CAR-T cells (BEAM-201) |
Overview Company | Beam Therapeutics Inc. |
Overview Modality | CGT |
Overview Target | T-Cell Acute Lymphoblastic Leukemia/Lymp |
Overview Indication | T-Cell Acute Lymphoblastic Leukemia/Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.. CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C→T deamination-mediated knockouts of TCRαβ, CD52, an… |
Toxicology CRS | Reported |
Clinical Safety signal | Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.. CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C→T deamination-mediated knockouts of TCRαβ, CD52, an… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201)) Beam Therapeutics Inc.·T-Cell Acute Lymphoblastic Leukemi… 16 trials |
|---|---|
Overview Program | Allogeneic anti-CD7 CAR-T cells (BEAM-201) |
Overview Company | Beam Therapeutics Inc. |
Overview Modality | CGT |
Overview Target | T-Cell Acute Lymphoblastic Leukemia/Lymp |
Overview Indication | T-Cell Acute Lymphoblastic Leukemia/Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.. CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C→T deamination-mediated knockouts of TCRαβ, CD52, an… |
Toxicology CRS | Reported |
Clinical Safety signal | Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.. CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C→T deamination-mediated knockouts of TCRαβ, CD52, an… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교